{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000007","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.888850+00:00","generated_at":"2026-06-07T03:53:29.809962+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexaria's DehydraTECH semaglutide outperforms Rybelsus in human pilot study","bullets":["DehydraTECH semaglutide showed 43% higher peak blood levels vs Rybelsus; levels higher at all 19 time points.","Blood glucose reduced by 5.01% at 24 hours vs baseline for DehydraTECH; Rybelsus group unchanged.","No moderate nausea or diarrhea reported with DehydraTECH; Rybelsus caused both side effects.","Lexaria preparing additional human and animal studies on expedited basis for GLP-1 drugs."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000007","json":"https://secwatch.observer/filing/0001640334-24-000007.json","markdown":"https://secwatch.observer/filing/0001640334-24-000007.md","text":"https://secwatch.observer/filing/0001640334-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000007/0001640334-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000007/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:53:29.809962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}